Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to $104818.0.

  • InMed Pharmaceuticals' Amortizatization of Intangibles rose 3814.38% to $104818.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $363904.0, marking a year-over-year increase of 137.0%. This contributed to the annual value of $321885.0 for FY2025, which is 1637.57% down from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Amortizatization of Intangibles stood at $104818.0, which was up 3814.38% from $103478.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $104818.0 in Q4 2025 and a low of $75876.0 during Q4 2024
  • Its 4-year average for Amortizatization of Intangibles is $92128.6, with a median of $93808.5 in 2023.
  • Data for InMed Pharmaceuticals' Amortizatization of Intangibles shows a peak YoY increase of 3814.38% (in 2025) and a maximum YoY decrease of 1932.56% (in 2025) over the last 5 years.
  • Over the past 4 years, InMed Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $90389.0 in 2022, then rose by 2.98% to $93085.0 in 2023, then dropped by 18.49% to $75876.0 in 2024, then soared by 38.14% to $104818.0 in 2025.
  • Its last three reported values are $104818.0 in Q4 2025, $103478.0 for Q3 2025, and $78330.0 during Q2 2025.